Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Journey Medical Corp
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 7.37 · gapped below the open, then crossed back over prior close. High/low 7.37 at 4:00 pm ET, 7.13 at 12:00 pm ET.
Journey Medical Corp has 5 disclosed suppliers and 2 disclosed customers. Each one is named in an SEC filing, either Journey Medical Corp’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Other revenue for the year ended December 31, 2025, reflects the supply to Cutia of Amzeeq for commercial use and sales-based royalties on Cutia's net sales of Amzeeq, pursuant to the Cutia Agreement.”
FILING10-K0001104659-26-034629cik 0001867066
“On May 21, 2025, we entered into a Manufacturing and Supply Agreement for Targadox (the "Targadox Agreement") with Epic Pharma, LLC ("Epic").”
FILING10-K0001104659-26-034629cik 0001867066
“On August 31, 2023, we entered into the New License Agreement with Maruho Co. Lts. ("Maruho"), whereby we granted an exclusive license to Maruho to develop and commercialize Qbrexza for the treatment of primary axillary hyperhidrosis in South Korea, Taiwan, Hong Kong, Macau, Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, Myanmar and Laos.”
FILING10-K0001104659-26-034629cik 0001867066
“On March 31, 2021, we executed an asset purchase agreement for Qbrexza (the "Qbrexza APA") with Dermira Inc. ("Dermira"), pursuant to which we acquired global ownership to Qbrexza (glycopyrronium), a prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine years of age and older.”
FILING10-K0001104659-26-034629cik 0001867066
“On December 18, 2020, we entered into an asset purchase agreement for our Anti-itch Product (the "Anti-itch APA") with Sun Pharmaceutical Industries, Inc. ("Sun").”
FILING10-K0001104659-26-034629cik 0001867066
“On January 12, 2022, we entered into an Asset Purchase Agreement (the "Vyne APA") with Vyne Therapeutics Inc. ("Vyne") to acquire Vyne's Molecule Stabilizing Technology™ franchise (the "Acquisition") for an upfront payment of $20.0 million, with an additional $5.0 million payment due on the one-year anniversary of the closing of the Acquisition.”
FILING10-K0001104659-26-034629cik 0001867066
“As part of the Qbrexza APA, we were assigned an exclusive license agreement with Rose University ("Rose U") pursuant to which we obtained a worldwide exclusive license within a field of use including hyperhidrosis to practice, enforce and otherwise exploit certain patent rights, know-how and data related to Qbrexza.”
FILING10-K0001104659-26-034629cik 0001867066
Watchlist prices, news filtered to it, and its next report on your desk.
DERM (Journey Medical Corp) has 5 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.